EGFR and non-small cell lung carcinoma: The identification of oncogenic driver alterations that can be targeted by EGFR tyrosine kinase inhibitors (EGFR-TKI: erlotinib, gefitinib, afatinib, dacotinib) for EGFR mutated tumors has improved median progression-free survival (PFS), overall response rates and quality of life in metastatic NSCLC patients, making EGFR TKIs the first-line treatment of choice in patients with EGFR mutation (EGFRm) advanced NSCLC [3].